3 Women-Led Biotech Companies Focusing on Epigenetic Therapy
Cognition Therapeutics Advancing Pipeline for Lead Candidate in Treatment of Neurodegenerative Disorders
EpiBone Breaking Boundaries, not Bones
Aetion’s Real World Evidence Platform Collaborates with FDA to Create Breakthroughs in Evaluating Covid-19
Enzyvant’s Rethymic to be the First FDtreatment for Pediatirc Congenital Athymia
LambdaVision Utilizing Bacteriorhodopsin to Bring Light To Sufferers of Age-Related Macular Degeneration and Retinitis Pigmentosa
SkinIO: Enabling Virtual Early Detection Powered by AI Image Skin Analysis
New Technologies
Intra-Cellular Therapies FDA Approval for Bipolar Disorder Associated with Depression 
Intra-Cellular Therapies ended the year 2021 with a big achievement. On December 20, 2021, Dr. Sharon Mates, Chairman, and CEO of Intra-Cellular Therapies announced the FDA approval of their medication, CAPLYTA. CAPLYTA (lumateperone) is currently the only medication approved to treat depressive disorders associated with bipolar I or bipolar II as monotherapy and in adjunct
- Intra-Cellular Therapies FDA Approval for Bipolar Disorder Associated with Depression 
- SkinIO: Enabling Virtual Early Detection Powered by AI Image Skin Analysis
- LambdaVision Utilizing Bacteriorhodopsin to Bring Light To Sufferers of Age-Related Macular Degeneration and Retinitis Pigmentosa
- Cognition Therapeutics Advances Lead Candidate in Treatment of Neurodegenerative Disorders
- 3 Women-Led Biotech Companies Focusing on Epigenetic Therapy
